TP Therapeutics

6 articles about TP Therapeutics

• TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study

  6/4/2018

  Preliminary antitumor activity observed in ROS1 fusion-positive NSCLC patients across multiple doses of TPX-0005 with additional responders pending confirmation Ten Confirmed RECIST Partial Responses (1 NTRK; 7 ROS1 TKI naïve; 2 ROS1 TKI pretreated) with longest duration of treatment of 13.4+ months and 70% of responses ongoing

• TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer

  5/14/2018

  TP Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapies with a focus on addressing current drug resistance.

• TP Therapeutics Appoints Lewis Shuster to Board of Directors

  2/27/2018

  TP Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced the appointment of Lewis “Lew” Shuster to the Company’s Board of Directors.

• TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor

  12/4/2017

  Dr. Gujrathi most recently served as Chief Medical Officer of Receptos.

• TP Therapeutics Announces FDA Orphan Drug Designation Granted To TPX-0005 For Treatment Of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, Or NTRK Oncogenic Rearrangements

  6/27/2017

• Pfizer Alum's TP Therapeutics Banks $45 Million Series C

  5/23/2017